160 related articles for article (PubMed ID: 28921520)
1. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
Jung S; Allen N; Arslan AA; Baglietto L; Barricarte A; Brinton LA; Egleston BL; Falk RT; Fortner RT; Helzlsouer KJ; Gao Y; Idahl A; Kaaks R; Krogh V; Merritt MA; Lundin E; Onland-Moret NC; Rinaldi S; Schock H; Shu XO; Sluss PM; Staats PN; Sacerdote C; Travis RC; Tjønneland A; Trichopoulou A; Tworoger SS; Visvanathan K; Weiderpass E; Zeleniuch-Jacquotte A; Dorgan JF
Int J Cancer; 2018 Jan; 142(2):262-270. PubMed ID: 28921520
[TBL] [Abstract][Full Text] [Related]
2. Circulating prolactin levels and risk of epithelial ovarian cancer.
Clendenen TV; Arslan AA; Lokshin AE; Liu M; Lundin E; Koenig KL; Berrino F; Hallmans G; Idahl A; Krogh V; Lukanova A; Marrangoni A; Muti P; Nolen BM; Ohlson N; Shore RE; Sieri S; Zeleniuch-Jacquotte A
Cancer Causes Control; 2013 Apr; 24(4):741-8. PubMed ID: 23378139
[TBL] [Abstract][Full Text] [Related]
3. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.
Schock H; Surcel HM; Zeleniuch-Jacquotte A; Grankvist K; Lakso HÅ; Fortner RT; Kaaks R; Pukkala E; Lehtinen M; Toniolo P; Lundin E
Endocr Relat Cancer; 2014; 21(6):831-44. PubMed ID: 25270324
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y; Pal T; Rosen B; McLaughlin JR; Sellers TA; Risch HA; Zhang S; Ping S; Narod SA; Schildkraut J
Int J Gynecol Cancer; 2013 Jul; 23(6):1010-5. PubMed ID: 23748177
[TBL] [Abstract][Full Text] [Related]
6. Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.
Matsuno RK; Sherman ME; Visvanathan K; Goodman MT; Hernandez BY; Lynch CF; Ioffe OB; Horio D; Platz C; Altekruse SF; Pfeiffer RM; Anderson WF
Cancer Causes Control; 2013 Apr; 24(4):749-57. PubMed ID: 23378140
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.
Fortner RT; Schock H; Jung S; Allen NE; Arslan AA; Brinton LA; Egleston BL; Falk RT; Gunter MJ; Helzlsouer KJ; Idahl A; Johnson TS; Kaaks R; Krogh V; Lundin E; Merritt MA; Navarro C; Onland-Moret NC; Palli D; Shu XO; Sluss PM; Staats PN; Trichopoulou A; Weiderpass E; Zeleniuch-Jacquotte A; Zheng W; Dorgan JF
Br J Cancer; 2017 Oct; 117(9):1412-1418. PubMed ID: 28873086
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y; Pal T; Rosen B; McLaughlin JR; Sellers TA; Risch HA; Zhang S; Sun P; Narod SA; Schildkraut J
Int J Gynecol Cancer; 2014 May; 24(4):664-9. PubMed ID: 24755492
[TBL] [Abstract][Full Text] [Related]
9. Anti-Mullerian hormone and risk of invasive serous ovarian cancer.
Schock H; Lundin E; Vääräsmäki M; Grankvist K; Fry A; Dorgan JF; Pukkala E; Lehtinen M; Surcel HM; Lukanova A
Cancer Causes Control; 2014 May; 25(5):583-9. PubMed ID: 24562905
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aspirin use and the risk of ovarian cancer in Denmark.
Baandrup L; Kjaer SK; Olsen JH; Dehlendorff C; Friis S
Ann Oncol; 2015 Apr; 26(4):787-792. PubMed ID: 25538177
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
12. Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.
Obón-Santacana M; Lujan-Barroso L; Travis RC; Freisling H; Ferrari P; Severi G; Baglietto L; Boutron-Ruault MC; Fortner RT; Ose J; Boeing H; Menéndez V; Sánchez-Cantalejo E; Chamosa S; Castaño JM; Ardanaz E; Khaw KT; Wareham N; Merritt MA; Gunter MJ; Trichopoulou A; Papatesta EM; Klinaki E; Saieva C; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Idahl A; Lundin E; Weiderpass E; Vesper HW; Riboli E; Duell EJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):127-34. PubMed ID: 26598536
[TBL] [Abstract][Full Text] [Related]
13. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
Kim SJ; Rosen B; Fan I; Ivanova A; McLaughlin JR; Risch H; Narod SA; Kotsopoulos J
Br J Cancer; 2017 Mar; 116(7):964-971. PubMed ID: 28208158
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
[TBL] [Abstract][Full Text] [Related]
15. Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.
Nichols HB; Baird DD; Stanczyk FZ; Steiner AZ; Troester MA; Whitworth KW; Sandler DP
Cancer Prev Res (Phila); 2015 Jun; 8(6):528-34. PubMed ID: 25873369
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for different histological types of ovarian cancer.
Parazzini F; Chiaffarino F; Negri E; Surace M; Benzi G; Franceschi S; Fedele L; La Vecchia C
Int J Gynecol Cancer; 2004; 14(3):431-6. PubMed ID: 15228415
[TBL] [Abstract][Full Text] [Related]
17. Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
Ge W; Clendenen TV; Afanasyeva Y; Koenig KL; Agnoli C; Brinton LA; Dorgan JF; Eliassen AH; Falk RT; Hallmans G; Hankinson SE; Hoffman-Bolton J; Key TJ; Krogh V; Nichols HB; Sandler DP; Schoemaker MJ; Sluss PM; Sund M; Swerdlow AJ; Visvanathan K; Liu M; Zeleniuch-Jacquotte A
Int J Cancer; 2018 Jun; 142(11):2215-2226. PubMed ID: 29315564
[TBL] [Abstract][Full Text] [Related]
18. Epidemiologic features of borderline ovarian tumors in California: a population-based study.
Morris CR; Liu L; Rodriguez AO; Cress RD; Snipes K
Cancer Causes Control; 2013 Apr; 24(4):665-74. PubMed ID: 23314731
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and risk of ovarian cancer.
Leitzmann MF; Koebnick C; Danforth KN; Brinton LA; Moore SC; Hollenbeck AR; Schatzkin A; Lacey JV
Cancer; 2009 Feb; 115(4):812-22. PubMed ID: 19127552
[TBL] [Abstract][Full Text] [Related]
20. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
